Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Breast Neoplasms 25Lymphoma 15Neutropenia 9Lymphoma, Large B-Cell, Diffuse 7Leukemia 7Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Lymphoma, Follicular 5Leukemia, Lymphocytic, Chronic, B-Cell 5Triple Negative Breast Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Hodgkin Disease 4Chemotherapy-induced Neutropenia 4Urinary Bladder Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Colorectal Neoplasms 3Burkitt Lymphoma 3Breast Neoplasms, Male 3Adenocarcinoma, Bronchiolo-Alveolar 3Adenocarcinoma of Lung 3Waldenstrom Macroglobulinemia 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2

Interventions

Radiotherapy 2Pyridoxine 2Etoposide 2Cytarabine 2Cyclophosphamide 2sodium thiosulfate 1pegfilgrastim 1pegaspargase 1etoposide phosphate 1Vincristine 1Triptorelin Pamoate 1Rituximab 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Dexrazoxane 1Dexamethasone 1Celecoxib 1Carboplatin 1Capecitabine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Drug-Related Side Effects and Adverse Reactions × pegfilgrastim × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡